Get to know our community, stay up to date on important industry news and learn about the latest happenings with Hemophilia B
People with an inherited bleeding disorder have a higher risk of low iron because of blood loss from bleeding. When low iron is not treated, it can turn into iron deficiency anemia over time.
London Health Sciences Centre (LHSC) has administered the first treatment in Canada using a new, one-time gene therapy that could replace a lifetime of Factor IX transfusions — a protein that helps stop bleeding.
Be Biopharma has ended its Phase 1/2 BeCoMe-9 study of BE-101, an investigational cell therapy for hemophilia B.
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Women and girls with inherited bleeding disorders (IBD) face distinct gynaecologic and obstetric challenges, largely due to increased bleeding risk during key reproductive milestones.
Adeno-associated virus (AAV)–mediated gene therapy has emerged as a promising treatment for hemophilia B.
The Coalition for Hemophilia B (CHB) is proud to announce that it has been awarded a New York State Senate Proclamation recognizing 35 years of service to individuals and families affected by hemophilia B.
The Coalition Calls on Congress to Pass Two Key Bills. Children with Rare Diseases Can't Wait.
This article, featured through Biomatrix, beautifully captures our mission and the journey of The Coalition for Hemophilia B over the past three and a half decades.
Millions of Americans depend on the Affordable Care Act (ACA) for health insurance, over 26 million people, including many living with chronic conditions.
Major Health Policy Changes Ahead:
What the 2025 Budget Reconciliation Act Means for People with Hemophilia B
Letter to Sec. Kennedy re: the Reinstatement of CDC's Division of Blood Disorders & Public Health Genomics
Critical changes at the CDC’s Division of Blood Disorders and Public Health Genomics affecting our community.
Industry News.
CSL Behring has announced that the first patient in the United States has received HEMGENIX®, which is currently the only approved gene therapy product for hemophilia B.
B Voice Advocacy News.
We want to keep you informed of the issues that underscore why advocacy matters. Check this page periodically for news and information.
We know that many of you are concerned about the future of federal funding for Hemophilia Treatment Centers (HTCs) given the uncertainty surrounding recent policy changes.
Making Treatment More Accessible: How Pediatric Vouchers Help Families Afford Hemophilia Care
Dana’s Living Her Life with No Regrets - Embracing Life with Hemophilia B and Finding Joy in Family Adventures
